文献速递痛风与晶体性关节病

别嘌醇降低死亡率的效果:观察性研究中的时间相关偏倚

Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies.
PubMed 文献 · Arthritis Rheumatol · 2021-07-27

该综述检索文献以评估别嘌醇使用与不使用对全因死亡率影响的观察性研究中的偏倚程度,共纳入12项观察性研究。存在永生时间偏倚或不可测量时间偏倚的研究显示别嘌醇与死亡率降低相关,而避免这些偏倚的6项研究则显示无显著效应(汇总HR 0.99,95%CI 0.87-1.11)。结论认为显示死亡率显著降低的观察性研究不能作为证据,主要由于时间相关偏倚会夸大治疗获益。

要点

  • 存在永生时间偏倚的研究汇总HR为0.71(95%CI 0.50-1.01)。
  • 存在不可测量时间偏倚的研究汇总HR为0.62(95%CI 0.56-0.67)。
  • 避免时间相关偏倚的6项研究汇总HR为0.99(95%CI 0.87-1.11)。

核心结论

  • 显示别嘌醇治疗显著降低死亡率的观察性研究不能作为证据,主要由于时间相关偏倚会大幅夸大潜在获益。

研究设计与样本

  • 文献综述,检索并纳入12项描述别嘌醇使用与不使用对全因死亡率影响的观察性研究。

主要发现

  • 3项研究受永生时间偏倚影响,其汇总HR为0.71(95%CI 0.50-1.01)。
  • 3项研究受不可测量时间偏倚影响,其汇总HR为0.62(95%CI 0.56-0.67)。
  • 剩余6项研究避免了上述时间相关偏倚,汇总HR为0.99(95%CI 0.87-1.11),显示别嘌醇对死亡率无显著效应。

关键数值与推荐

  • 避免时间相关偏倚的6项研究汇总HR为0.99(95%CI 0.87-1.11)。
  • 存在永生时间偏倚的研究汇总HR为0.71(95%CI 0.50-1.01)。
  • 存在不可测量时间偏倚的研究汇总HR为0.62(95%CI 0.56-0.67)。

临床怎么用

  • 解读别嘌醇与死亡率相关的观察性研究时需警惕时间相关偏倚,不应将其作为降低死亡率的证据。
  • 正在进行的ALL-HEART随机试验将提供别嘌醇对死亡率影响的可靠证据。

局限性

  • 避免偏倚的6项研究缺乏基于治疗依从性的分析,可能减弱了效应估计。
  • 综述仅纳入观察性研究,未提供随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares. Several observational studies have shown important reductions in mortality with allopurinol use, with wide variations in results. We undertook this review to assess the extent of bias in these studies, particularly time-related biases such as immortal time bias. METHODS: We searched the literature to identify all observational studies describing the effect of allopurinol use versus nonuse on all-cause mortality. RESULTS: We identified 12 observational studies, of which 3 were affected by immortal time bias and 3 by immeasurable time bias, while the remaining 6 studies avoided these time-related biases. Reductions in all-cause mortality with allopurinol use were observed among the studies with immortal time bias, with a pooled hazard ratio (HR) of death associated with allopurinol of 0.71 (95% confidence interval [95% CI] 0.50-1.01), as well as in those with immeasurable time bias (pooled HR 0.62 [95% CI 0.56-0.67]). The 6 studies that avoided these biases demonstrated a null effect of allopurinol on mortality (pooled HR 0.99 [95% CI 0.87-1.11]), though the lack of an analysis based on treatment adherence may have attenuated the effect. CONCLUSION: Observational studies are important to provide real-world data on medication effects. The observational studies showing significantly decreased mortality with allopurinol treatment cannot be used as evidence, however, mainly due to time-related biases that tend to greatly exaggerate the potential benefit of treatments. The ALL-HEART randomized trial, which is currently underway and evaluates the effect of adding allopurinol to usual care (compared to no added treatment), will provide reliable evidence on mortality.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Suissa S, Suissa K, Hudson M, et al. Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. Arthritis Rheumatol. 2021. PMID: 33645906. doi:10.1002/art.41710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。